Boehringer Ingelheim announces the initiation of clinical trial, a new 12 week study to assess the safety, tolerability and pharmacokinetics of add-on treatment with pirfenidone to background therapy with OFEV in patients with idiopathic pulmonary fibrosis (IPF). The trial’s primary endpoint is the percentage of patients with on-treatment gastrointestinal (GI) adverse events from baseline to week 12.
IPF is a rare condition that causes thickening and scarring of the lung tissue over time, a process known as fibrosis. This fibrosis limits the amount of oxygen that can be delivered to the major organs and also causes difficulty breathing. The median survival of IPF patients following diagnosis is just 2-3 years, underlining the importance of early and accurate diagnosis and the vital role of treatments that can help to slow disease progression.
